Relevant Interviews, Disease and Trial Updates and Stock-Markets News posted by CRISPR Medicine News.

Check also Companies to Follow in 2022 and CMN Markets for the latest stock and market trends.

Always stay updated with the free CMN Newsletter.

Prime Medicine

Main focus: Prime editing for the treatment of genetic diseases

Company stage: Pre-clinical

Diseases: Undisclosed

Genome editing tool: Prime editing

Funding stage: Private

Location: Cambridge, MA, USA


Gene editing partnerships: Beam Therapeutics

Prime Medicine is a start-up company that focuses on prime editing. Prime editing is a novel CRISPR-derived gene-editing technology, which was first disclosed in October 2019. Although the company has not revealed its first pre-clinical candidate, it launched with $315M in combined Series A and B funding. The company is co-founded by Professor David R. Liu, who also co-founded Editas Medicine, Beam Therapeutics, Pairwise Plants and Exo Therapeutics.


HashtagPrime Medicine

The CMN Collection of Delivery Articles
Company: Prime Medicine
Jobs, banner ads, webinars, sponsored content...
Search CRISPR Medicine